比较单纯预防性全脑照射与预防性全脑照射联合巩固性颅外照射治疗广泛期小细胞肺癌的随机II期研究:NRG Oncology RTOG 0937
NRG Oncology RTOG 0937是一项随机II期试验,评估广泛期小细胞肺癌患者预防性全脑照射(PCI)或PCI联合巩固性颅外照射(PCI+cRT)的1年总生存(OS)。研究因无效边界提前终止,PCI组与PCI+cRT组1年OS无显著差异,PCI+cRT延缓了疾病进展但未改善1年OS。
要点
- PCI组与PCI+cRT组1年OS分别为60.1%与50.8%,无显著差异(p=0.21)。
- PCI+cRT组疾病进展时间优于PCI组(HR=0.53,95%CI 0.32-0.87,p=0.01)。
- PCI+cRT组有1例治疗相关5级肺炎,每组各有1例4级治疗相关毒性。
核心结论
- 两组的OS均超过预期,cRT延缓了疾病进展但未改善1年OS。
研究设计与样本
- 随机II期试验,入组对化疗完全缓解或部分缓解后具有1至4个颅外转移灶的广泛期小细胞肺癌患者。
- 随机分配至PCI组或PCI+cRT组(照射胸部及转移灶),按化疗后部分缓解vs完全缓解、1个vs 2至4个转移灶分层,后增加年龄<65岁vs≥65岁分层。
- PCI方案为25 Gy分10次,cRT方案为45 Gy分15次。
- 计划检测OS从30%提高至45%(风险比=0.66,34%风险降低),单侧α=0.1,把握度80%,需154例患者。
- 2010年3月至2015年2月共随机97例,排除11例不合格(PCI组9例,PCI+cRT组2例),最终PCI组42例、PCI+cRT组44例。
主要发现
- 中位随访9个月,1年OS在PCI组为60.1%(95%CI 41.2-74.7),在PCI+cRT组为50.8%(95%CI 34.0-65.3),两组无显著差异(p=0.21)。
- 3个月和12个月进展率在PCI组分别为53.3%和79.6%,在PCI+cRT组分别为14.5%和75%。
- 疾病进展时间 favoring PCI+cRT(风险比=0.53,95%CI 0.32-0.87,p=0.01)。
- 每组各有1例4级治疗相关毒性,PCI+cRT组有1例5级治疗相关肺炎。
局限性
- 研究因计划中期分析时跨越OS无效边界而提前终止,未达到计划的入组目标154例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: NRG Oncology RTOG 0937 is a randomized phase II trial evaluating 1-year overall survival (OS) with prophylactic cranial irradiation (PCI) or PCI plus consolidative radiation therapy (PCI+cRT) to intrathoracic disease and extracranial metastases for extensive-disease SCLC. METHODS: Patients with one to four extracranial metastases were eligible after a complete response or partial response to chemotherapy. Randomization was to PCI or PCI+cRT to the thorax and metastases. Original stratification included partial response versus complete response after chemotherapy and one versus two to four metastases; age younger than 65 years versus 65 years or older was added after an observed imbalance. PCI consisted of 25 Gy in 10 fractions. cRT consisted of 45 Gy in 15 fractions. To detect an improvement in OS from 30% to 45% with a 34% hazard reduction (hazard ratio = 0.66) under a 0.1 type 1 error (one sided) and 80% power, 154 patients were required. RESULTS: A total of 97 patients were randomized between March 2010 and February 2015. Eleven patients were ineligible (nine in the PCI group and two in the PCI+cRT group), leaving 42 randomized to receive PCI and 44 to receive PCI+cRT. At planned interim analysis, the study crossed the futility boundary for OS and was closed before meeting the accrual target. Median follow-up was 9 months. The 1-year OS was not different between the groups: 60.1% (95% confidence interval [CI]: 41.2-74.7) for PCI and 50.8% (95% CI: 34.0-65.3) for PCI+cRT (p = 0.21). The 3- and 12-month rates of progression were 53.3% and 79.6% for PCI and 14.5% and 75% for PCI+cRT, respectively. Time to progression favored PCI+cRT (hazard ratio = 0.53, 95% CI: 0.32-0.87, p = 0.01). One patient in each arm had grade 4 therapy-related toxicity and one had grade 5 therapy-related pneumonitis with PCI+cRT. CONCLUSIONS: OS exceeded predictions for both arms. cRT delayed progression but did not improve 1-year OS.
引用
- Gore EM, Hu C, Sun AY, et al. Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extracranial Irradiation for Extensive-Disease Small Cell Lung Cancer (ED SCLC): NRG Oncology RTOG 0937. J Thorac Oncol. 2017. PMID: 28648948. doi:10.1016/j.jtho.2017.06.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。